No black box warning on record for Tivdak

As of the latest FDA labeling reviewed, Tivdak (TISOTUMAB VEDOTIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tivdak medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Peripheral neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. ( 2.3 , 5.2 ) • Hemorrhage: Monitor patients for signs and symptoms of hemorrhage. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. ( 2.3 , 5.3 ) • Pneumonitis: Severe, life-th

No black box warning on record for Tivdak

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Peripheral neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. ( 2.3 , 5.2 ) • Hemorrhage: Monitor patients for signs and symptoms of hemorrhage. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. ( 2.3 , 5.3 ) • Pneumonitis: Severe, life-th

Tivdak Black Box Warning

No black box warning on record for Tivdak

Other warnings & precautions

Tivdak Black Box Warning

No black box warning on record for Tivdak

Other warnings & precautions